Group 1: Financial Performance - Standard BioTools reported a quarterly loss of $0.04 per share, consistent with the Zacks Consensus Estimate, compared to a loss of $0.08 per share a year ago [1] - The company posted revenues of $41.96 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 5.35%, and up from $37.21 million year-over-year [2] - The current consensus EPS estimate for the upcoming quarter is -$0.04 on revenues of $40.7 million, and for the current fiscal year, it is -$0.14 on revenues of $169.3 million [7] Group 2: Market Performance - Standard BioTools shares have declined approximately 25.4% since the beginning of the year, while the S&P 500 has gained 8.6% [3] - The company has surpassed consensus revenue estimates three times over the last four quarters, but has only exceeded consensus EPS estimates once in the same period [2][1] Group 3: Industry Outlook - The Medical Info Systems industry, to which Standard BioTools belongs, is currently ranked in the top 36% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor decisions [5]

Company Performance - Maravai LifeSciences Holdings, Inc. reported a quarterly loss of $0.08 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.06, marking an earnings surprise of -33.33% [1] - The company posted revenues of $47.4 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 2.23%, and a significant decline from year-ago revenues of $73.4 million [2] - Over the last four quarters, Maravai has not surpassed consensus EPS estimates and has topped consensus revenue estimates only once [2] Stock Performance - Maravai LifeSciences shares have declined approximately 59.6% since the beginning of the year, contrasting with the S&P 500's gain of 8.6% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.05 on revenues of $50.74 million, and for the current fiscal year, it is -$0.24 on revenues of $196.21 million [7] Industry Outlook - The Medical - Products industry, to which Maravai belongs, is currently ranked in the bottom 38% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of Maravai's stock may be influenced by the overall outlook for the industry, as research shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Company Performance - Aquestive Therapeutics reported a quarterly loss of $0.14 per share, better than the Zacks Consensus Estimate of a loss of $0.18, representing an earnings surprise of +22.22% [1] - The company posted revenues of $10 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 9.62%, and a decline from year-ago revenues of $20.1 million [2] - Over the last four quarters, the company has surpassed consensus EPS estimates just once and topped consensus revenue estimates only once [2] Stock Movement and Outlook - Shares of Aquestive Therapeutics have increased by approximately 9.6% since the beginning of the year, outperforming the S&P 500's gain of 8.6% [3] - The sustainability of the stock's price movement will depend on management's commentary during the earnings call and future earnings expectations [3][4] - The current consensus EPS estimate for the upcoming quarter is -$0.17 on revenues of $12.33 million, and for the current fiscal year, it is -$0.72 on revenues of $45.27 million [7] Industry Context - The Medical - Drugs industry, to which Aquestive Therapeutics belongs, is currently in the top 35% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5][6]

Company Performance - Assertio reported a quarterly loss of $0.17 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.10, and compared to a loss of $0.04 per share a year ago, indicating a significant decline in performance [1] - The company posted revenues of $29.22 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 4.55%, but down from $31.13 million in the same quarter last year [2] - Over the last four quarters, Assertio has surpassed consensus EPS estimates only once and has topped consensus revenue estimates two times [2] Stock Movement and Outlook - Assertio shares have declined approximately 16.3% since the beginning of the year, contrasting with the S&P 500's gain of 8.6% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $31.2 million, and for the current fiscal year, it is -$0.27 on revenues of $117.81 million [7] Industry Context - The Medical - Drugs industry, to which Assertio belongs, is currently ranked in the top 35% of over 250 Zacks industries, suggesting a favorable environment for stocks in this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - The estimate revisions trend for Assertio was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6]

Company Performance - Aris Water Solutions reported quarterly earnings of $0.19 per share, missing the Zacks Consensus Estimate of $0.24 per share, representing an earnings surprise of -20.83% [1] - The company posted revenues of $124.09 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 3.61%, compared to year-ago revenues of $101.12 million [2] - Over the last four quarters, Aris Water Solutions has surpassed consensus revenue estimates four times, but has only exceeded EPS estimates once [2] Stock Performance - Aris Water Solutions shares have lost about 1.4% since the beginning of the year, while the S&P 500 has gained 8.6% [3] - The current Zacks Rank for Aris Water Solutions is 5 (Strong Sell), indicating expected underperformance in the near future [6] Future Outlook - The current consensus EPS estimate for the coming quarter is $0.28 on revenues of $122.99 million, and for the current fiscal year, it is $1.04 on revenues of $485.6 million [7] - The outlook for the Waste Removal Services industry, where Aris Water Solutions operates, is currently in the bottom 28% of Zacks industries, which may impact stock performance [8]

Company Performance - Celanese reported quarterly earnings of $1.44 per share, exceeding the Zacks Consensus Estimate of $1.38 per share, but down from $2.38 per share a year ago, indicating an earnings surprise of +4.35% [1] - The company posted revenues of $2.53 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.42%, although this is a decrease from year-ago revenues of $2.65 billion [2] - Over the last four quarters, Celanese has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times [2] Stock Performance - Celanese shares have declined approximately 30.6% since the beginning of the year, contrasting with the S&P 500's gain of 8.6% [3] - The current Zacks Rank for Celanese is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is $1.77 on revenues of $2.54 billion, and for the current fiscal year, it is $5.13 on revenues of $9.85 billion [7] - The outlook for the Chemical - Specialty industry, where Celanese operates, is currently in the bottom 35% of over 250 Zacks industries, which may impact the stock's performance [8]

Core Viewpoint - Getty Images Holdings, Inc. reported a quarterly loss of $0.08 per share, missing the Zacks Consensus Estimate of $0.03, and showing a significant decline from earnings of $0.01 per share a year ago, resulting in an earnings surprise of -366.67% [1][2] Financial Performance - The company posted revenues of $234.88 million for the quarter ended June 2025, which was 0.61% below the Zacks Consensus Estimate, but an increase from $229.14 million in the same quarter last year [2] - Over the last four quarters, Getty Images has not surpassed consensus EPS estimates and has only topped revenue estimates twice [2] Stock Performance - Shares of Getty Images have declined approximately 21.8% since the beginning of the year, contrasting with the S&P 500's gain of 8.6% [3] - The current Zacks Rank for Getty Images is 3 (Hold), indicating that the stock is expected to perform in line with the market in the near future [6] Earnings Outlook - The consensus EPS estimate for the upcoming quarter is $0.03 on revenues of $242.78 million, while the estimate for the current fiscal year is -$0.16 on revenues of $952.28 million [7] - The trend of earnings estimate revisions is mixed, which could change following the recent earnings report [6] Industry Context - The Internet - Software industry, to which Getty Images belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting that companies in the top half tend to outperform those in the bottom half by more than 2 to 1 [8]

Core Insights - Perion Network (PERI) reported quarterly earnings of $0.26 per share, exceeding the Zacks Consensus Estimate of $0.17 per share, with an earnings surprise of +52.94% [1] - The company posted revenues of $102.98 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.49%, although this represents a decline from year-ago revenues of $108.69 million [2] - Perion Network shares have increased approximately 20.5% year-to-date, outperforming the S&P 500's gain of 8.6% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.26 on revenues of $110.5 million, and for the current fiscal year, it is $0.99 on revenues of $440.66 million [7] - The estimate revisions trend for Perion Network was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Internet - Content industry, to which Perion Network belongs, is currently ranked in the top 41% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Similarweb (SMWB), another company in the same industry, is expected to report a quarterly loss of $0.00 per share, with revenues projected at $68.88 million, reflecting a year-over-year increase of 13.6% [9]

Core Insights - Clearside Biomedical, Inc. reported a quarterly loss of $0.06 per share, outperforming the Zacks Consensus Estimate of a loss of $0.12, marking a 50% earnings surprise [1] - The company achieved revenues of $0.49 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 87.07%, compared to revenues of $0.09 million a year ago [2] - The stock has underperformed, losing approximately 59.7% since the beginning of the year, while the S&P 500 has gained 7.8% [3] Financial Performance - Over the last four quarters, Clearside Biomedical has surpassed consensus EPS estimates four times [2] - The current consensus EPS estimate for the upcoming quarter is -$0.08 on revenues of $0.26 million, and for the current fiscal year, it is -$0.38 on revenues of $3.22 million [7] Market Outlook - The company's earnings outlook is crucial for assessing future stock performance, with a favorable trend in estimate revisions leading to a Zacks Rank 2 (Buy) [6] - The Medical - Biomedical and Genetics industry is currently ranked in the bottom 43% of over 250 Zacks industries, which may impact stock performance [8]

Core Viewpoint - ProFrac Holding Corp. reported a quarterly loss of $0.67 per share, significantly worse than the Zacks Consensus Estimate of a loss of $0.29, marking an earnings surprise of -131.03% [1] Financial Performance - The company posted revenues of $501.9 million for the quarter ended June 2025, slightly exceeding the Zacks Consensus Estimate by 0.52%, but down from $579.4 million in the same quarter last year [2] - Over the last four quarters, ProFrac has surpassed consensus EPS estimates two times and topped revenue estimates three times [2] Stock Performance - ProFrac Holding Corp. shares have declined approximately 19.2% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] Future Outlook - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is -$0.27 on revenues of $477.65 million, and for the current fiscal year, it is -$0.98 on revenues of $1.99 billion [7] Industry Context - The Oil and Gas - Field Services industry, to which ProFrac belongs, is currently ranked in the bottom 9% of over 250 Zacks industries, indicating a challenging environment [8]